Forte Biosciences, Inc. (FBRX) Stock Grade

About Forte Biosciences, Inc.'s fundamentals

Forte Biosciences is a $1.6 billion biotechnology company that reported flat revenue with zero year-over-year growth and a net loss in its latest annual statement, resulting in a 0.0% net margin. The company does not pay a dividend and lacks meaningful profitability metrics typical of established pharmaceutical firms. As an early-stage biotech company, Forte's financial profile reflects the capital-intensive nature of drug development, where revenue generation and profitability remain limited while the company funds research and development activities.